Patients If GLP-1s work too well, what happens next for metabolic dis... What happens if GLP-1s work too well?
R&D Sponsored The future of cardiometabolic trials: From obesity to outcom... Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO
R&D BIO-Europe Spring 2026: In conversation with Robert Jacks Robert Jacks, CEO of Sparrow Pharmaceuticals, discusses the company’s work in the cardiometabolic space.
R&D Sponsored Best practices in cardiometabolic trial design: Planning and... Cardiometabolic disease is not a single entity. It is a broad spectrum of disorders that share common drivers.
R&D Looking ahead to 2026 in biopharma A look forward to trends to come in 2026, including AI-driven drug development, advanced modalities, and cardiometabolic disease therapies.
News Novo Nordisk Foundation gives $75m for R&D 'challenges' The Novo Nordisk Foundation's latest round of R&D funding will go towards projects in biomanufacturing, cardiometabolic diseases, and AI.
Oncology Dr Michael Bauer on Quantro’s mission to drug the “undruggab... Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
